Acute cold allodynia induced by oxaliplatin is attenuated by amitriptyline

Furgała, Agata; Sałat, Robert; Sałat, Kinga

doi:10.21307/ane-2018-030

Cited by 10 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For all temperatures tested, early‐phase cold allodynia was fully developed 3 hr after oxaliplatin injection, so for further experiments that involved measurements of predrug latencies to pain reaction this time point was chosen. Earlier studies also confirmed that after a single dose of oxaliplatin, cold allodynia is stable for at least 7 days, and therefore, this period was involved in the in vivo testing (Furgała, Sałat, et al., ; Nakagawa & Kaneko, ). It is worth noting that although the device we use (hot/cold plate apparatus, Bioseb, France) is supplied with a thermo‐controller which enables to maintain the temperature constantly at the desired level, each day prior to the testing session, the temperature of the plate was carefully checked by using a thermocouple probe. We used one (type BM807) purchased from Brymen Technology Corporation (Taiwan), but any device of this type and precision can be used.…”

Section: Methodsmentioning

confidence: 75%

“…For further pain tests, only mice with baseline latencies ≥40 s were chosen. In this assay, the maximum observation time (i.e., cut‐off time) was 60 s. In our earlier experiments, we tested a broader temperature range—from 1 to 4°C (Furgała, Sałat, & Sałat, ) and cold allodynia was measured at various time points: 2, 3, 4, 6, 24 hr, 3, and 7 days after oxaliplatin. We found that the development of cold allodynia could be observed as early as 2 hr after oxaliplatin administration, which is consistent with the previously published data (Nakagawa & Kaneko, ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Searching for analgesic drug candidates alleviating oxaliplatin‐induced cold hypersensitivity in mice

2019

Self Cite

View full text Add to dashboard Cite

Oxaliplatin is a third‐generation, platinum‐based derivative used to treat advanced colorectal cancer. Within the patient population on oxaliplatin therapy, a lower incidence of hematological adverse effects and gastrointestinal toxicity is noted, but severe neuropathic pain episodes characterized by increased cold and tactile hypersensitivity are present in ~95% of patients. This drug is also used to induce a rodent model of chemotherapy‐induced peripheral neuropathy (CIPN)‐related neuropathic pain which is widely used in the search for novel therapies for CIPN prevention and treatment. This paper provides a step‐by‐step, detailed description of the prevention and intervention protocols used in our laboratory for the assessment of oxaliplatin‐induced cold allodynia in mice. To establish cold sensitivity in mice, the cold plate test was used. Latencies to pain reaction in response to cold stimulus (2.5°C) for vehicle‐treated non‐neuropathic mice, vehicle‐treated mice injected with oxaliplatin (neuropathic control), and oxaliplatin‐treated mice treated additionally with duloxetine are compared. Duloxetine is a serotonin/noradrenaline reuptake inhibitor which was found to produce significant pain relief in patients with CIPN symptoms. In our present study, duloxetine administered intraperitoneally at the dose of 30 mg/kg served as a model antiallodynic drug which attenuated or partially prevented cold allodynia caused by oxaliplatin.

show abstract

Section: Methodsmentioning

confidence: 75%

Section: Methodsmentioning

confidence: 99%

Searching for analgesic drug candidates alleviating oxaliplatin‐induced cold hypersensitivity in mice

2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The effect of 1 on cold pain threshold was assessed using the cold plate test [ 73 , 74 ]. In this assay, after the establishment of predrug latency to pain reaction for each animal, the mice were treated with the test compounds and 60 min later they were placed on the cold plate apparatus (Hot/cold plate, Bioseb, France) set at 2.5 °C and were observed for the appearance of a nocifensive response (hind paw licking, shaking, jumping or abnormal movements).…”

Section: Methodsmentioning

confidence: 99%

Phenylalanine-Based AMPA Receptor Antagonist as the Anticonvulsant Agent with Neuroprotective Activity—In Vitro and In Vivo Studies

et al. 2022

Self Cite

View full text Add to dashboard Cite

Trying to meet the multitarget-directed ligands strategy, a series of previously described aryl-substituted phenylalanine derivatives, reported as competitive antagonists of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, were screened in vitro for their free-radical scavenging and antioxidant capacity in two different assays: ferric reducing antioxidant power (FRAP) and oxygen radical absorbance capacity fluorescent (ORAC-FL) assays. The most active antioxidants 1 and 8 were further examined to evaluate their neuroprotective properties in vitro. In this study, compound 1 showed a significant neuroprotective effect against the neurotoxin 6-hydroxydopamine in neuroblastoma SH-SY5Y and IMR-32 cell lines. Both compounds also showed prevention from high levels of reactive oxygen species (ROS) in SH-SY5Y cells. Furthermore, the desired monoamine oxidase B (MAO-B) inhibition effect (IC50 = 278 ± 29 nM) for 1 was determined. No toxic effects up to 100 µM of 1 and 8 against neuroblastoma cells were observed. Furthermore, in vivo studies showed that compound 1 demonstrated significant anticonvulsant potential in 6-Hz test, but in neuropathic pain models its antiallodynic and antihyperalgesic properties were not observed. Concluding, the compound 1 seems to be of higher importance as a new phenylalanine-based lead candidate due to its confirmed promise in in vitro and in vivo anticonvulsant activity.

show abstract

“…Here, the animal placed on the cooled plate at 5°C and the time to induce nociceptive behaviour indicated by shivering and paw licking recorded as the response time (Furgula et.al., 2018).…”

Section: Methodsmentioning

confidence: 99%

Attenuation of Hyperalgesia and Allodynia by some Phenolic Acids in Paclitaxel Induced Neuropathy

Pawar¹,

Upaganlawar²,

Upasani³

2021

Preprint

View full text Add to dashboard Cite

Paclitaxel, an anticancer drug induced neuropathy is widely used animal model to evaluate new drugs in neuropathy. As oxidative stress is key contributor in pathogenesis of neuropathy, many phenolic acids with antioxidant potential are proven as neuroprotective. So,present work undertaken to evaluate effect of syringic acid and sinapic acid in paclitaxel induced neuropathy. We evaluated effect on mechanical and thermal hyperalgesia and allodynia which are vital signs of neuropathy. 4 weeks treatment by different doses of syringic acid and sinapic acid shown significant protective effect on hyperalgesia and allodynia in dose dependant manner assessed by Randello Selitto, hot plate, cold plate and Von Frey filament test. As these phenolic acids attenuates hyperalgesia and allodynia in neuropathy, can be therapeutically used in combination with current treatment of neuropathy.Summary statementHyperlagesia and allodynia are major signs of neuropathy and this article focus on reduction of hyperalgesia and allodynia by syringic and sinapic acid in neuropathy induced by paclitaxel.

show abstract

Acute cold allodynia induced by oxaliplatin is attenuated by amitriptyline

Cited by 10 publications

References 32 publications

Searching for analgesic drug candidates alleviating oxaliplatin‐induced cold hypersensitivity in mice

Searching for analgesic drug candidates alleviating oxaliplatin‐induced cold hypersensitivity in mice

Phenylalanine-Based AMPA Receptor Antagonist as the Anticonvulsant Agent with Neuroprotective Activity—In Vitro and In Vivo Studies

Attenuation of Hyperalgesia and Allodynia by some Phenolic Acids in Paclitaxel Induced Neuropathy

Contact Info

Product

Resources

About